🔴 Tscan Therapeutics is trading 5% down today alongside Nasdaq Composite's 0.54% decline

Tscan Therapeutics is trading 5.34% down at $0.26, alongside broader market weakness; no specific company catalyst was identified.

• No company-specific announcement dated October 8 was identified. The latest release listed on the company’s investor-relations page is dated September 2 and describes a strategic reorganization.
• The Nasdaq Composite is down 0.54%, alongside higher-yield and oil-related concerns in the supplied market context. This is consistent with broader risk-off sentiment, but does not establish a specific company catalyst.